NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for its oral formulation of TPOXX® (tecovirimat).  TPOXX is a novel small molecule antiviral therapy for smallpox infection. SIGA requested priority review of its TPOXX NDA at the time the filing was submitted because smallpox infection is a deadly disease for which no cure or treatment currently exists. The FDA advised that it has granted priority review to the application, meaning that the agency will target completing its review in six rather than ten months. In light of the NDA submission on December 8, 2017, the FDA has notified SIGA that the agency’s target final action date is August 8, 2018.

The U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) funded the advanced development of oral TPOXX in partnership with SIGA. Additionally, under Project Bioshield, BARDA has purchased two million courses of oral TPOXX and such courses have been delivered to the Strategic National Stockpile (SNS).

“We are very pleased that the FDA has accepted our NDA for oral TPOXX. This is an important milestone in the regulatory review of our pending application. Based on a comprehensive submission that includes extensive positive efficacy data in animal studies and human clinical safety data without any drug-related Serious Adverse Events, we look forward to a favorable, expedited review of the application,” said Dr. Phil Gomez, Chief Executive Officer of SIGA Technologies, Inc.“A positive FDA review would represent an important milestone not only for SIGA, but for our federal government partners that have provided invaluable support throughout development of the product. Our public-private collaboration serves as an important example of how such partnerships can advance novel drugs for unmet medical needs. Eventual approval of this product would be an important step in advancing health security against the serious threat of a potential smallpox-based bioterror attack.”

TPOXX (tecovirimat) was developed under the FDA “Animal Rule,” in which efficacy endpoints are determined in animal studies, and human clinical studies are conducted to determine safety and confirm dosing. The TPOXX NDA comprised extensive positive efficacy data in animal studies and human clinical safety data demonstrating that there have been no drug-related Serious Adverse Events during the development of oral TPOXX.